Recommendations for classification of commercial LBA kits for biomarkers in drug development from the GCC for bioanalysis
Over the last decade, the use of biomarker data has become integral to drug development. Biomarkers are not only utilized for internal decision-making by sponsors; they are increasingly utilized to make critical decisions for drug safety and efficacy. As the regulatory agencies are routinely making decisions based on biomarker data, there has been significant scrutiny on the validation of biomarker methods. Contract research organizations regularly use commercially available immunoassay kits to validate biomarker methods. However, adaptation of such kits in a regulated environment presents significant challenges and was one of the key topics discussed during the 12th Global Contract Research Organization Council for Bioanalysis (GCC) meeting. This White Paper reports the GCC members' opinion on the challenges facing the industry and the GCC recommendations on the classification of commercial kits that can be a win-win for commercial kit vendors and end users.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Bioanalysis - 11(2019), 7 vom: 24. Apr., Seite 645-653 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Islam, Rafiq [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BAV |
|---|
| Anmerkungen: |
Date Completed 15.08.2019 Date Revised 15.08.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/bio-2019-0072 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM296146676 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM296146676 | ||
| 003 | DE-627 | ||
| 005 | 20231225085215.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2019-0072 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0987.xml |
| 035 | |a (DE-627)NLM296146676 | ||
| 035 | |a (NLM)30993999 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Islam, Rafiq |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recommendations for classification of commercial LBA kits for biomarkers in drug development from the GCC for bioanalysis |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.08.2019 | ||
| 500 | |a Date Revised 15.08.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Over the last decade, the use of biomarker data has become integral to drug development. Biomarkers are not only utilized for internal decision-making by sponsors; they are increasingly utilized to make critical decisions for drug safety and efficacy. As the regulatory agencies are routinely making decisions based on biomarker data, there has been significant scrutiny on the validation of biomarker methods. Contract research organizations regularly use commercially available immunoassay kits to validate biomarker methods. However, adaptation of such kits in a regulated environment presents significant challenges and was one of the key topics discussed during the 12th Global Contract Research Organization Council for Bioanalysis (GCC) meeting. This White Paper reports the GCC members' opinion on the challenges facing the industry and the GCC recommendations on the classification of commercial kits that can be a win-win for commercial kit vendors and end users | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BAV | |
| 650 | 4 | |a CRO | |
| 650 | 4 | |a GCC | |
| 650 | 4 | |a LBA | |
| 650 | 4 | |a bioanalysis | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a commercial kits | |
| 650 | 4 | |a immunoassay | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 650 | 7 | |a Reagent Kits, Diagnostic |2 NLM | |
| 700 | 1 | |a Kar, Sumit |e verfasserin |4 aut | |
| 700 | 1 | |a Ritzén, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Hays, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Tayyem, Rabab |e verfasserin |4 aut | |
| 700 | 1 | |a Barry, Colin |e verfasserin |4 aut | |
| 700 | 1 | |a Keyhani, Anahita |e verfasserin |4 aut | |
| 700 | 1 | |a Zimmer, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Cruz Caturla, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Couerbe, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Warren, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Khadang, Ardeshir |e verfasserin |4 aut | |
| 700 | 1 | |a Bourdage, James |e verfasserin |4 aut | |
| 700 | 1 | |a Lindley, Kathie |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Dave |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Sheldon, Curtis |e verfasserin |4 aut | |
| 700 | 1 | |a Satterwhite, Christina |e verfasserin |4 aut | |
| 700 | 1 | |a Vija, Jenifer |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Mathilde |e verfasserin |4 aut | |
| 700 | 1 | |a Boulay, Iohann |e verfasserin |4 aut | |
| 700 | 1 | |a Stamatopoulos, John |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Jenny |e verfasserin |4 aut | |
| 700 | 1 | |a Cape, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Estdale, Sian |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Dinan, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a MacNeill, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Yi Qun |e verfasserin |4 aut | |
| 700 | 1 | |a Garofolo, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Savoie, Natasha |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Rhyne, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Hristopoulos, George |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Arron |e verfasserin |4 aut | |
| 700 | 1 | |a Goodwin, Lawrence |e verfasserin |4 aut | |
| 700 | 1 | |a Spriggs, Franklin |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Allan |e verfasserin |4 aut | |
| 700 | 1 | |a Awaiye, Kayode |e verfasserin |4 aut | |
| 700 | 1 | |a Hayes, Roger |e verfasserin |4 aut | |
| 700 | 1 | |a St Charles, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Bouhajib, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a DiMarco, Chantal |e verfasserin |4 aut | |
| 700 | 1 | |a DiMarco, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Savu, Simona Rizea |e verfasserin |4 aut | |
| 700 | 1 | |a Bennett, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Kakkanaiah, Vellalore |e verfasserin |4 aut | |
| 700 | 1 | |a Nehls, Corey |e verfasserin |4 aut | |
| 700 | 1 | |a Stouffer, Bruce |e verfasserin |4 aut | |
| 700 | 1 | |a Tabler, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Briscoe, Chad |e verfasserin |4 aut | |
| 700 | 1 | |a Karnik, Shane |e verfasserin |4 aut | |
| 700 | 1 | |a DuBey, Ira |e verfasserin |4 aut | |
| 700 | 1 | |a Kulagina, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Lindsay, John |e verfasserin |4 aut | |
| 700 | 1 | |a Beaver, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Williard, Clark |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Malone, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Wells, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Xinping |e verfasserin |4 aut | |
| 700 | 1 | |a Moussallie, Marc |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g 11(2019), 7 vom: 24. Apr., Seite 645-653 |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:7 |g day:24 |g month:04 |g pages:645-653 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2019-0072 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 7 |b 24 |c 04 |h 645-653 | ||